Publications by authors named "E A Horowitz"

Background: Pregnancy can be a complex and stressful period, especially for women conceiving through fertility treatment, but this can foster the experience of personal growth (PG). Most of the knowledge on women's PG during pregnancy is based on a single measurement and relates to conceiving achieved through fertility treatments in general. Relying on Schaefer and Moos's PG model, the current prospective study sought to (1) investigate the differences in PG according to women's mode of conception (spontaneous; first-line fertility treatment; IVF) and (2) examine the contribution of the mode of conception, perceived stress, self-mastery, and cognitive appraisal (threat, challenge, and self-efficacy) to PG in two phases during pregnancy.

View Article and Find Full Text PDF
Article Synopsis
  • Planned oocyte cryopreservation (OC) is gaining popularity, but some women struggle to obtain enough oocytes due to poor ovarian response, which can be classified using the POSEIDON system.
  • In a study of 160 patients, 39.4% were identified as POSEIDON patients, showing significant differences compared to non-POSEIDON patients in terms of hormone levels and oocyte retrieval.
  • The findings indicate that POSEIDON patients have a higher need for fertility medications and retrieve fewer oocytes, highlighting the importance of this classification for patient counseling and management in OC procedures.
View Article and Find Full Text PDF

In 2022, 3.7 million children were born in the United States, of whom ∼600 000 received care from a neonatologist. The dramatic growth of the neonatal-perinatal medicine (NPM) workforce from 375 in 1975 to 5250 in 2022 has paralleled exploding clinical demand.

View Article and Find Full Text PDF

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant condition of multiple myeloma with few known risk factors. The emergence of mass spectrometry (MS) for the detection of MGUS has provided new opportunities to evaluate its risk factors. In total, 2628 individuals at elevated risk for multiple myeloma were enrolled in a screening study and completed an exposure survey (PROMISE trial).

View Article and Find Full Text PDF